Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00003392
Status:
COMPLETED
Last Update Posted:
2012-02-22
First Post:
1999-11-01
Brief Title:
High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer
Sponsor:
UNC Lineberger Comprehensive Cancer Center
Organization:
UNC Lineberger Comprehensive Cancer Center
Study Overview
Official Title:
Multiple Cycles of High Dose Chemotherapy Supported With Filgrastim and Peripheral Blood Progenitor Cells in Patients With Metastatic Breast Cancer
Status:
COMPLETED
Status Verified Date:
2012-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells
PURPOSE Phase II trial to study the effectiveness of high-dose chemotherapy and peripheral stem cell transplantation in treating patients with recurrent or refractory metastatic breast cancer
PURPOSE Phase II trial to study the effectiveness of high-dose chemotherapy and peripheral stem cell transplantation in treating patients with recurrent or refractory metastatic breast cancer
Detailed Description:
OBJECTIVES I Determine the effects on 2 year progression-free survival of a regimen consisting of cyclophosphamide paclitaxel and filgrastim G-CSF to mobilize peripheral blood progenitor cells PBPCs followed by 2 courses of carboplatin and paclitaxel followed by 1 course of melphalan each supported with PBPCs and G-CSF in patients with recurrent or refractory advanced breast cancer II Evaluate the feasibility of administering multiple courses of high dose chemotherapy in an outpatient setting for these patients III Evaluate the rate of complete response to the high dose therapy in these patients
OUTLINE This is a multicenter study Patients receive mobilization therapy consisting of cyclophosphamide IV over 1 hour followed by paclitaxel IV over 3 hours then filgrastim G-CSF beginning 24 hours following completion of paclitaxel and continuing through the last day of leukapheresis Leukapheresis continues until an adequate number of CD34 cells is collected Following cell count recovery patients receive 3 courses of high-dose chemotherapy 2 courses of paclitaxel IV over 3 hours followed by carboplatin IV over 1 hour with the first course generally within 21 days after completion of leukapheresis and the second course 21-35 days after the first then 1 course of melphalan IV infused over 30 minutes 21-35 days after the previous carboplatin dose Each course of chemotherapy is followed 24-48 hours later by the infusion of G-CSF-mobilized peripheral blood progenitor cells and G-CSF Patients are followed every 3 months for 2 years
PROJECTED ACCRUAL A total of 96 evaluable patients will be accrued for this study over 3 years
OUTLINE This is a multicenter study Patients receive mobilization therapy consisting of cyclophosphamide IV over 1 hour followed by paclitaxel IV over 3 hours then filgrastim G-CSF beginning 24 hours following completion of paclitaxel and continuing through the last day of leukapheresis Leukapheresis continues until an adequate number of CD34 cells is collected Following cell count recovery patients receive 3 courses of high-dose chemotherapy 2 courses of paclitaxel IV over 3 hours followed by carboplatin IV over 1 hour with the first course generally within 21 days after completion of leukapheresis and the second course 21-35 days after the first then 1 course of melphalan IV infused over 30 minutes 21-35 days after the previous carboplatin dose Each course of chemotherapy is followed 24-48 hours later by the infusion of G-CSF-mobilized peripheral blood progenitor cells and G-CSF Patients are followed every 3 months for 2 years
PROJECTED ACCRUAL A total of 96 evaluable patients will be accrued for this study over 3 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| UNC-LCCC-970135 | OTHER | None | None |
| NCI-G98-1446 | OTHER_GRANT | NCI | None |